Clinical management of renal transplant patients with donor-specific alloantibody: the state of the art.

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Our understanding of the role of DSA in both early and late renal allograft injury has advanced significantly over the past decade. Novel protocols have been developed that have led to improved outcomes both in overcoming a positive crossmatch and in the treatment of early AMR. Early experience with bortezomib and eculizumab are encouraging and suggest the possibility of validation in controlled clinical trials. While alloantibody remains an extremely difficult clinical problem and it is unclear if overcoming early hurdles will only be followed by another major hurdle of chronic antibody mediated injury. However, it is clear that significant advances have occurred and if future studies can be designed appropriately, then our ability to control alloantibody in sensitized patients will continue to improve.

Original languageEnglish (US)
Pages (from-to)307-315
Number of pages9
JournalClinical transplants
StatePublished - 2010

Fingerprint

Isoantibodies
Tissue Donors
Transplants
Kidney
Controlled Clinical Trials
Wounds and Injuries
Allografts
Antibodies
Therapeutics
Bortezomib
eculizumab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9283468d20f2430aa7403bb00941bc06,
title = "Clinical management of renal transplant patients with donor-specific alloantibody: the state of the art.",
abstract = "Our understanding of the role of DSA in both early and late renal allograft injury has advanced significantly over the past decade. Novel protocols have been developed that have led to improved outcomes both in overcoming a positive crossmatch and in the treatment of early AMR. Early experience with bortezomib and eculizumab are encouraging and suggest the possibility of validation in controlled clinical trials. While alloantibody remains an extremely difficult clinical problem and it is unclear if overcoming early hurdles will only be followed by another major hurdle of chronic antibody mediated injury. However, it is clear that significant advances have occurred and if future studies can be designed appropriately, then our ability to control alloantibody in sensitized patients will continue to improve.",
author = "Stegall, {Mark D}",
year = "2010",
language = "English (US)",
pages = "307--315",
journal = "Clinical transplants",
issn = "0890-9016",
publisher = "UCLA Immunogenetics Center",

}

TY - JOUR

T1 - Clinical management of renal transplant patients with donor-specific alloantibody

T2 - the state of the art.

AU - Stegall, Mark D

PY - 2010

Y1 - 2010

N2 - Our understanding of the role of DSA in both early and late renal allograft injury has advanced significantly over the past decade. Novel protocols have been developed that have led to improved outcomes both in overcoming a positive crossmatch and in the treatment of early AMR. Early experience with bortezomib and eculizumab are encouraging and suggest the possibility of validation in controlled clinical trials. While alloantibody remains an extremely difficult clinical problem and it is unclear if overcoming early hurdles will only be followed by another major hurdle of chronic antibody mediated injury. However, it is clear that significant advances have occurred and if future studies can be designed appropriately, then our ability to control alloantibody in sensitized patients will continue to improve.

AB - Our understanding of the role of DSA in both early and late renal allograft injury has advanced significantly over the past decade. Novel protocols have been developed that have led to improved outcomes both in overcoming a positive crossmatch and in the treatment of early AMR. Early experience with bortezomib and eculizumab are encouraging and suggest the possibility of validation in controlled clinical trials. While alloantibody remains an extremely difficult clinical problem and it is unclear if overcoming early hurdles will only be followed by another major hurdle of chronic antibody mediated injury. However, it is clear that significant advances have occurred and if future studies can be designed appropriately, then our ability to control alloantibody in sensitized patients will continue to improve.

UR - http://www.scopus.com/inward/record.url?scp=79960061687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960061687&partnerID=8YFLogxK

M3 - Article

C2 - 21696048

AN - SCOPUS:79960061687

SP - 307

EP - 315

JO - Clinical transplants

JF - Clinical transplants

SN - 0890-9016

ER -